Brentuximab vedotin - Seagen/Takeda Oncology
At a glance
- Drug Originator Seattle Genetics; Stanford University
- Drug Licenced by Takeda Oncology
- Drug Class Antineoplastics; Antiretrovirals; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies; Oligopeptides; Skin disorder therapies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
- USA Patent Applicants SEATTLE GENETICS
- USA Patents 73
- BLAs 2
- International Patents 553
Disclaimer